Dr. Talbot is a neurobiologist and postmortem investigator well known for his studies on the molecular basis of Alzheimer’s disease (AD) and schizophrenia for nearly twenty years. He received his Ph.D. in behavioral neuroscience from UCLA in 1989. He received postdoctoral training in neurodegenerative disease research in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania (1997-2001), where he then served as a senior investigator in the Department of Psychiatry (2001 to 2007) and later as an assistant professor in that department (2008 to 2012). Between 2004 and 2012, his research led to two major discoveries: (1) that the first protein genetically linked to schizophrenia risk by positional cloning, dysbindin-1, is commonly reduced in synapses of schizophrenia cases and plays a role in their marked cognitive deficits and (2) that brain insulin resistance is a common feature in AD and Parkinson's disease (PD) cases and is closely associated with their cognitive deficits. Since 2013, Dr. Talbot's research has been conducted in southern California as a faculty member at Cedars-Sinai Medical Center, UCLA, and most recently at Loma Linda University School of Medicine, where he is an Associate Professor in the Departments of Pathology and Human Anatomy, Neurosurgery, and Basic Sciences. With the support of NIH, he heads a collaboration among 4 U.S. laboratories focused on identifying the molecular causes of brain insulin resistance in AD and PD, as well as its alleviation by agonists of receptors for the incretins GLP-1 and GIP. Dr. Talbot's research has been funded by the Alzheimer’s Association and the National Institute on Aging in the U.S., as well as by the Cure Parkinson's Trust in the U.K. His findings have been published in leading journals such as Nature Medicine, PNAS, Molecular Psychiatry, and the Journal of Clinical Investigation. He has given invited lectures on his research at national and international conferences in the U.S., Denmark, Poland, Japan and the U.K. sponsored by such organizations as Alzheimer's Association, American College of Neuropsychopharmacology, the Society for Neuroscience, and the World Congress on Psychiatric Genetics. Dr. Talbot's long-term research goal is the development of a clinically effective, disease modifying treatments for AD and PD, progress on which is the subject of his talk at the 2021 AD/PD conference.